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Three new antiepileptic drugs (AEDs) are finding increasing use in medical practice. To examine their efficacy and 
side-effect profile, 483 patients with epilepsy attending either a specialized epilepsy clinic or general neurology 
clinic under the care of a single consultant neurologist were reviewed. Of these patients 127 had received 
lamotrigine, 100 vigabatrin and 27 gabapentin. In all but three patients the indication had been epilepsy refractory 
to other treatments. 
Efficacy was confirmed if patients achieved a >50% reduction in seizure frequency or became seizure free. By 
this criteria 36.3% of patients receiving lamotrigine, 29% receiving vigabatrin and 15% receiving gabapentin 
benefited significantly. 
Lack of efficacy was the major reason for discontinuing vigabatrin (27%) and gabapentin (33.3%) whereas an 
adverse vent was the main reason in patients receiving lamotrigine (28.3%). 
A spectrum of adverse vents were noted. Behavioural/psychological effects in particular occurred with all of the 
drugs and frequently necessitated drug withdrawal. There was also a suggestion of a pharmacodynamic interaction 
between lamotrigine and both carbamazepine and sodium valproate resulting in toxicity of these latter drugs in a 
few patients. 
Drug tolerance was suspected in 12% of patients receiving vigabatrin, less frequently in those on gabapentin and 
only rarely with lamotrigine. 
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INTRODUCTION 
Epilepsy is a common condition with a prevalence 
of around 0.5% of the population ~. It has a 
particularly high psychosocial morbidity 2 and is a 
significant cause of premature and sudden death 3. 
Accordingly the ultimate goal in patients with 
epilepsy is to render them seizure free without 
inducing adverse vents. In the majority of cases 
this can be achieved using a single well estab- 
lished agent such as sodium valproate, car- 
bamazepine or phenytoin. However, in a sig- 
nificant minority of patients, particularly those 
with complex partial seizures and secondarily 
generalized partial seizures, mono- or poly- 
therapy with such agents proves unsuccessful. In
these circumstances the new AEDs, vigabatrin, 
lamotrigine and gabapentin are increasingly used 
as adjunctive therapy. These agents have been 
licensed for use since 1989, 1991 and 1993, 
respectively. 
Vigabatrin works by inhibiting the enzyme 
GABA transaminase and thereby raises the levels 
of GABA, an inhibitory neurotransmitter. 
Lamotrigine acts by blocking voltage-dependent 
sodium channels thereby stabilizing neuronal 
membranes and reducing the release of excitatory 
neurotransmitters such as glutamate and aspart- 
ate. Whilst gabapentin is a structural analogue of 
GABA, it does not affect its neuronal content or 
uptake, or bind to its receptors and its mechanism 
of antiepileptic action remains undefined. 
The main purpose of this audit was to examine 
the efficacy and tolerability of these new AEDs in 
clinical practice. Secondary aims were to assess 
the extent of their use and to build up a profile of 
the patients in whom they are employed. 
METHODS 
Four hundred and eighty-three patients attending 
either a specialized epilepsy clinic or general 
neurology clinic between September 1994 and 
1059-1311/96/020127 + 04 $12.00/0 © 1996 British Epilepsy Association 
128 G.V. McDonnell & J.h Morrow 
February 1995 were assessed. All of the patients 
were under the care of a single consultant 
neurologist (JIM) and were attending one of 
several centres throughout Northern Ireland at 
the Royal Victoria, Belfast City, Antrim, Mid- 
Ulster, Waveney, Moyle and Carrick Hospitals. 
The current and previous drug therapy was 
reviewed when those patients exposed to any of 
the three new AEDs were identified and the 
duration of epilepsy and the seizure frequency 
before and during treatment was established. All 
patients were categorized appropriately as to 
seizure type. 
A drug was deemed to be efficacious if it 
rendered a pateint seizure free for at least six 
months or produced a >50% reduction in seizure 
frequency. All significant adverse vents reported 
by patients were recorded irrespective of whether 
it resulted in drug discontinuation. 
RESULTS" 
One hundred and seventy-two (35.6%) of the 
patients surveyed had received at least one of 
lamotrigine, vigabatrin or gabapentin at some 
stage. There were 94 females and 78 males with 
an age range of 26-63 years (mean, 35 years). 
One hundred and twenty-seven patients had 
received lamotrigine, 100 vigabatrin and 27 
gabapentin. Apart from three patients com- 
menced on lamotrigine as part of a first-line 
monotherapy trial, the indication had been 
epilepsy refractory to other treatments. 
The duration of epilepsy ranged from onset (3 
cases) to 50 years (average, 20.3 years). Seizure 
frequency ranged from zero (3 cases) to 
224/month with an average frequency of 
18.3/month and a median frequency of 4 month. 
As can be seen from Table 1, the vast majority 
of patients had partial seizures with or without 
secondary generalization. These types of seizures 
are usually more difficult to control than primary 
Table 1: Categorization of patient by seizure type 
Seizure type No. 
patients (%) 
Simple partial seizures only 3 (1.7) 
Simple partial + complex partial seizures 12 (7.0) 
Complex partial seizures only 81 (47.1) 
Complex partial + tonic/clonic seizures 35 (20.3) 
Secondarily generalized tonic/clonic 28 (16.3) 
seizures 
Primary generalized seizures 13 (7.6) 
generalized seizures (which occurred in only a 
small portion of the group. 
Of those patients commenced on lamotrigine, 
71 (56%) were continuing on the drug at the time 
of the audit. Corresponding figures for vigabatrin 
and gabapentin were 45 (45%) and 13 (48.1%), 
respectively. In most cases the new AEDs formed 
part of a polytherapy r6gime but in nine patients 
on lamotrigine, five on vigabatrin and one on 
gabapentin they represented monotherapy. 
Excluding the three patients in the mono- 
therapy trial from onset of epilepsy, lamotrigine 
produced a >50% reduction in seizure frequency 
in 40 patients and rendered a further five seizure 
free giving a total efficacy of 36.3%. Vigabatrin 
produced a >50% reduction in 24 patients and 
rendered five patients eizure free (29% efficacy), 
whilst gabapentin enabled one patient o become 
seizure free and another three to have a >50% 
reduction in seizure frequency (15% efficacy). In 
addition to this definite benefit regarding seizure 
frequency a small and similar proportion of 
patients (3-4%) reported a decrease in seizure 
severity without a decrease in seizure frequency 
with each of the drugs. 
Of the 11 patients (6.5%) rendered seizure free 
none had been exposed to more than one of the 
new AEDs. Nine of these patients had complex 
partial seizures only, one had a combination of 
both simple partial and complex partial seizures 
and one had primary generalized epilepsy. This 
select group of patients had a higher average 
(29 vs. 18.3/month) and median (14 vs. 4/month) 
seizure frequency than for the group as a whole 
but had a shorter average duration of epilepsy 
(11.1 vs. 20.3 years). 
Because of the apparent discrepancy between 
the efficacies of lamotrigine and vigabatrin and 
that of gabapentin, the profile of patients 
receiving abapentin was examined more closely. 
Twenty-five of 27 patients (92.6%) had already 
received lamotrigine and/or vigabatrin prior to 
commencing gabapentin, 16 (59.3%) having 
received both. The average duration of epilepsy 
of the group was 23.3 years whilst the average and 
median seizure frequencies were 19.3/month and 
6/month, respectively. 
Significant adverse events were many and 
various and some patients experienced more than 
one (Table 2). The specific behavioural/ 
psychological adverse events described with 
lamotrigine were depression (five patients), 
aggressive behaviour (four patients), obsessional 
behaviour (two patients), confusion (two 
patients), anxiety (two patients) and reduced 
concentration span (one patient). 
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Lamotrigine 
No. (%) Withdrawn 
Event No. (%) 
Vigabatrin 
No. (%) 
Gabapentin 
Withdrawn No. (%) Withdrawn 
No. (%) No. (%) 
Psychological/ 16 (12.6) 11 (8.7) 
behavioural change 
Increased seizure 15 (11.8) 13 (10.2) 
frequency 
Drowsiness 7 (5.5) 2 (1.6) 
Skin rash 6 (4.7) 6 (4.7) 
Light headed/dizziness 6 (4.7) 2 (1.6) 
Nausea vomiting 4 (3.1) 2 (1.6) 
Headache 2 (1.6) 2 (1.6) 
Weight gain 1 (0.8) 0 
Diplopia 8 (6.3) 1 (0.8) 
Postural tremor 3 (2.4) 0 
Hair loss 1 (0.8) 0 
17 (17) 
7 (7) 
16 (16) 
0 
4 (4) 
3 (3) 
4 (4) 
6 (6) 
0 
0 
0 
12 (12) 2 (7.4) 2 
7 (7) 2 (7.4) 1 
6 (6) 4 (14.8) 2 
0 0 0 
1 (1) 3 (11.1) I 
2 (2) l (3.7) 1 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
(7.4) 
(3.7) 
(7.4) 
(3.7) 
(3.7) 
The skin rash occurring with lamotrigine 
became apparent <2 weeks after commencement 
of the drug in all but one patient and five of the 
six patients were having concomitant treatment 
with sodium valproate. All of those patients 
describing diplopia on lamotrigine were already 
established on carbamazepine and each of those 
experiencing weight gain, hair loss and postural 
tremor were previously on sodium valproate. 
Tolerance of effect was noted in 12 patients on 
vigabatrin, two having been seizure free and 10 
having had a >50% reduction in seizure fre- 
quency. This phenomenon was also noted in two 
patients having had a >50% reduction in seizures 
on gabapentin and one previously having similar 
benefit with lamotrigine. 
Overall, adverse events resulted in drug with- 
drawal in 28.3% on lamotrigine, 23% on vigabat- 
rin and 18.5% on gabapentin. Lack of efficacy 
preceded rug withdrawal in 15% on lamotrigine, 
27% on vigabatrin and 33.3% on gabapentin. In 
addition 5% of patients on vigabatrin were 
withdrawn due to drug tolerance and one patient 
(0.8%) discontinued lamotrigine due to 
pregnancy. 
DISCUSSION 
Epilepsy is a common condition in the community 
confronting neurologists, physicians and general 
practitioners alike. Indeed the average general 
practice might expect to have 10 patients with 
epilepsy, three of whom may be refractory to 
treatment. After a long period during which the 
treatment options for this latter group of patients 
had remained static, recent years have seen the 
development of several new agents. This has been 
most welcome and will hopefully continue. 
However, apart from creating opportunities these 
developments give rise to important questions 
about efficacy, tolerability, interactions and ap- 
propriate indications particularly in view of the 
cost of the new AEDs compared to the well 
established rugs. 
In our study the extent of exposure to at least 
one of the new AEDs was high (35.6%). In the 
light of previous experience it is unsurprising that 
they were generally used in patients having 
partial seizures (92.4%). Superficially at least, it 
might be said that the results on efficacy are 
disappointing iven that the primary goal is to 
render patients eizure free and this was achieved 
in only 6.5% of cases. However this was a group 
of patients with a long history of resistant, 
frequent and predominantly partial seizures in 
whom approximately one-third derived sig- 
nificant benefit from both lamotrigine and viga- 
batrin. The lower efficacy found with gabapentin, 
whilst in line with the results of others 4, may 
represent a slightly unfair reflection on the drug 
given that in over 90% of patients at least one of 
the other two new drugs had already been tried. 
As it is the most recently available of the new 
AEDs by some two years it may tend to be used 
in the most resistant of cases and in our practice it 
does seem to have often been used as a treatment 
of last resort. Also recent experience in the USA 
would suggest hat an optimal dosage of gaba- 
pentin may be 2.4 g/day 5 which is rather higher 
than the dosage received by the earlier patients in 
our group. 
Tolerability of the three agents varied although 
the range of common adverse vents was broadly 
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similar. Gabapentin which, like vigabatrin, is not 
metabolized in the liver and is excreted un- 
changed in the urine was the best tolerated whilst 
28.3% on lamotrigine which undergoes hepatic 
metabolism withdrew due to adverse vents. 
Behavioural/psychological side effects have 
been well described with vigabatrin 6 but this audit 
has found them occurring with all three drugs and 
leading to drug discontinuation in >70% of those 
affected. Predictably increased seizure frequency 
when it occurs almost invariably leads to drug 
discontinuation (87.5% of cases) and overall is 
the second commonest cause of drug withdrawal. 
Although frequently overcome, drowsiness was 
found to be a significant problem with vigabatrin 
and gabapentin. 
The occurrence of skin rash with lamotrigine 
was broadly in line with expectations at around 
5% 7 .The finding that all but one of these patients 
was concurrently on sodium valproate, a hepatic 
enzyme inhibitor, emphasizes the need to com- 
mence lamotrigine at a lower dosage and more 
slowly in such circumstances. 
Diplopia is a well known toxic effect of 
carbamazepine as are tremor, hair loss and weight 
gain with sodium valproate. However in a 
significant number of patients in this study these 
effects did not materialize until after starting 
lamotrigine. As lamotrigine had no effect on the 
pharmacokinetics of either drug this suggests a
pharmacodynamic interaction. This is further 
suggested as in our experience these effects 
disappeared with a reduction in dosage of 
carbamazepine or sodium valproate. Many of 
these and other effects of lamotrigine can be 
prevented by starting with a small initial dose, 
building up gradually and reducing the dosage of 
concomitant AEDs as side effects appear. 
Drug tolerance is a deterioration occurring 
after an initially favourable outcome which fails 
to improve despite subsequent alteration in 
dosage. It has been previously described with 
vigabatrin 8 and occurred in 12% of our patients 
on vigabatrin but was not a problem with 
lamotrigine. It may also prove to be a significant 
feature with gabapentin although larger numbers 
and a longer period of follow-up are required to 
assess this than were available in our study. 
This study reflects the wider choice of drugs 
available to treat refractory epilepsy. Naturally 
none of the three new AEDs addresses all or even 
most of the problems faced but they do represent 
a significant addition to patient management. As
they remain relatively 'young' drugs, further 
evaluation of their long-term efficacy and tolera- 
bility is required whilst the search for improved 
broad spectrum successors with no interactions 
and few side-effects continues. 
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